Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001046618 | SCV001210527 | likely benign | not provided | 2024-08-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002552599 | SCV003695189 | uncertain significance | Inborn genetic diseases | 2021-07-21 | criteria provided, single submitter | clinical testing | The c.452A>T (p.Q151L) alteration is located in exon 5 (coding exon 5) of the COL9A1 gene. This alteration results from a A to T substitution at nucleotide position 452, causing the glutamine (Q) at amino acid position 151 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Ce |
RCV001046618 | SCV004159702 | likely benign | not provided | 2022-03-01 | criteria provided, single submitter | clinical testing | COL9A1: BP4 |
Gene |
RCV001046618 | SCV005628418 | uncertain significance | not provided | 2024-07-16 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |